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1 |  INTRODUCTION
Obesity is a rapidly growing public health concern and 
accurate measures of body fatness are needed to clarify 
its role in the incidence and prognosis of prostate cancer 
(PCa).1 In most previous observational studies, body 
mass index (BMI), a marker of general obesity, has been 
found to be negatively associated with the risk of local-
ised PCa, and positively associated with advanced PCa 
risk.2- 4 However, in our recent study including 32,871 
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Abstract
We recently found a negative association between body mass index (BMI) and the 
risk of localised prostate cancer (PCa), no association with advanced PCa, and a posi-
tive association with PCa- specific mortality. In a 15% subpopulation of that study, we 
here investigated the measures of abdominal adiposity including waist circumference 
(WC) and A Body Shape Index (ABSI) in relation to PCa risk and mortality. We used 
data from 58,457 men from four Swedish cohorts to assess WC and ABSI in rela-
tion to PCa risk according to cancer risk category, including localised asymptomatic 
and symptomatic PCa and advanced PCa, and PCa- specific mortality. Cox regres-
sion models were used to calculate hazard ratios (HRs) and 95% confidence intervals 
(CIs). During, on average, 10  years of follow- up, 3290 men were diagnosed with 
PCa and 387 died of PCa. WC was negatively associated with the risk of total PCa 
(HR per 10 cm, 0.95; 95% CI 0.92– 0.99), localised PCa (HR per 10 cm, 0.93, 95% 
CI 0.88– 0.96) and localised asymptomatic PCa cases detected through a prostate- 
specific antigen (PSA) test (HR per 10 cm, 0.87, 95% CI 0.81– 0.94). WC was not 
associated with the risk of advanced PCa (HR per 10 cm, 1.02, 95% CI 0.93– 1.14) or 
with PCa- specific mortality (HR per 10 cm, 1.04, 95% CI 0.92– 1.19). ABSI showed 
no associations with the risk of PCa or PCa- specific mortality. While the negative 
association between WC and the risk of localised PCa was partially driven by PSA- 
detected PCa cases, no association was found between abdominal adiposity and clini-
cally manifest PCa in our population.
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incident PCa cases5 and another large pooled analysis by 
Genkinger et al,6 only little evidence was found for an 
association between BMI and the risk of more advanced 
PCa. Also, findings from Mendelian randomisation stud-
ies suggest no strong evidence of a causal effect of BMI on 
PCa.7,8 In addition to BMI, anthropometric measures of 
abdominal adiposity including waist circumference (WC) 
are also suggested to influence PCa incidence. Although 
less consistent, studies investigating WC and PCa risk 
also found mostly null or negative associations with lo-
calised PCa risk but null or positive associations with 
advanced PCa risk.3,4,6,9- 12 A body shape index (ABSI), 
a measure based on WC, weight and height and indepen-
dent from BMI, showed no association with the risk of 
PCa.10 The various findings for anthropometric measures 
across PCa risk categories, and the different prognosis of 
PCa even within specific subgroups,13 highlight the di-
versity of PCa and the need for further investigation by 
use of detailed clinical characteristics of the PCa.
The differential associations of PCa by disease severity 
have been hypothesised to be attributed to clinical char-
acteristics of men with obesity that may influence the de-
tection of PCa, such as a lower serum prostate- specific 
antigen (PSA) concentration,14- 16 and a larger prostate 
gland compared to normal weight men, which may lower 
the detection through biopsy.17 Moreover, more active 
screening behaviour in normal weight men compared to 
men with obesity may be involved. In our aforementioned 
study, we found that the negative association between BMI 
and the risk of localised PCa was partially driven by PCa 
cases detected through asymptomatic testing,5 which sup-
ports a role for detection bias in the obesity– PCa associ-
ation. To the best of our knowledge, no other prospective 
study has tested the prevailing hypothesis that the nega-
tive association between adiposity and the risk of localised 
PCa may be partly driven by localised PCa cases detected 
through PSA- testing.
Despite the lack of an association between BMI and 
more advanced PCa in our previous study,5 we, and a large 
number of other studies, found a positive association be-
tween BMI and the risk of PCa- specific mortality.6,18- 22 
Only a few studies reported findings for WC and PCa- 
specific mortality, which varied from no association23,24 
to a positive association.3,6 Although ABSI has been 
found to be positively associated with all- cause mortal-
ity,25- 27 its role in cancer- specific mortality has yet to be 
confirmed.26
We investigated the associations between abdominal 
adiposity measures including WC and ABSI and PCa risk, 
by cancer risk category and the reason for PCa detection 
(asymptomatic or symptomatic), and PCa- specific mortal-
ity, in a subset of men of our previous study of body size 
and PCa.
2 |  METHODS
2.1 | Study population
Out of the five cohorts included in our original investiga-
tion of general obesity and PCa,5 the Swedish Construction 
Workers Cohort [CWC] (‘Bygghälsan’),28 the Västerbotten 
Intervention Programme [VIP],29,30 the Northern Sweden 
Monica [MONICA] study,29,31 the Malmö Diet and Cancer 
Study [MDCS]32 and the Malmö Preventive Project [MPP],33 
WC had been measured in all but the largest cohort, the CWC, 
and only during later years in the VIP (2003 onwards), and 
during a re- examination period (2002– 2006) in the MPP. In 
all cohorts, height, weight and WC were measured at a health 
examination by trained staff.
2.2 | Selection criteria
After excluding examinations: from duplicate cohorts in men 
who had participated in more than one cohort, performed be-
fore 18 years of age, with a prevalent cancer (excluding non- 
melanoma skin cancer), with mismatching dates, and with 
missings for WC, height or weight, a total of 58,457 men 
were included in the study, comprising approximately 15% 
of the population in our previous study.5
2.3 | Follow- up
The unique personal identification number of all inhabitants 
in Sweden was used to follow- up cohort participants in na-
tional registers until 31 December 2016. The Swedish Cancer 
Register34 was used for the identification of diagnoses of PCa 
cases (International Classification of Diseases, version seven 
[ICD- 7] codes 177 or ICD- 10 C61) and other cancers. To 
obtain information on the primary underlying cause of death, 
the Swedish Cause of Death Register35 was used, which has 
a concordance of 86% with medical records for PCa- related 
deaths. Individuals were also linked to other nationwide reg-
isters including the Total Population Register for informa-
tion on migration, the Longitudinal Integration Database for 
Health Insurance and Labour Market Studies (LISA) for in-
formation on socioeconomic factors and country of birth, and 
the Patient Register for information on in- patient care which 
we used for the Charlson comorbidity index.36
The National Prostate Cancer Register (NPCR) of Sweden 
became nationwide in 1998 has captured 99% of all cases of 
PCa, and was used to classify PCa cases into five risk groups 
according to clinical information at PCa diagnosis: localised 
low- risk (T1- 2, Gleason score 2– 6 and PSA < 10 ng/ml), lo-
calised intermediate risk (T1- 2, Gleason score 7 and/or PSA 
10– <20 ng/ml), localised high risk (T3 and/or Gleason score 
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8– 10 and/or PSA 20 to <50  ng/ml), regionally metastatic/
locally advanced (T4 and/or N1 and/or PSA 50 to <100 ng/
ml in the absence of distant metastases [M0 or Mx]) or dis-
tant metastases (M1 and/or PSA ≥ 100 ng/ml).37,38 Localised 
PCa was further investigated by the main reason for detecting 
the disease, which was recorded as of the year 2000 and was 
categorised into asymptomatic detection (through a PSA- 
test) and symptomatic detection including lower urinary tract 
symptoms (LUTS) or any other symptoms.
2.4 | Statistical analysis
Cox regression models with attained age as the time scale 
were used to calculate hazard ratios (HRs) and 95% confi-
dence intervals (95% CIs) for PCa incidence according to 
cancer risk category and detection mode of localised PCa, 
and for PCa- specific mortality, by levels of WC (per 10 cm 
increase and categories <94, 94– 102, >102 cm), ABSI (per 
standard deviation increase) and BMI (per 5 kg/m2 increase) 
in the full population. Person- years for each individual were 
counted from the date of study enrolment until the date of a 
first PCa diagnosis, another cancer diagnosis (excluding non- 
melanoma skin cancer), emigration, death or end of follow- up 
(31 December 2016). Follow- up in the analysis of PCa risk 
category and by detection mode started on 1 January 1998 
or 2000, respectively, or at study enrolment, whichever oc-
curred last. Models were stratified for cohort and birth period 
(<1935, 1935– 1939, 1940– 1944, 1945– 1949 and ≥1950), 
and adjustment for the a priori chosen variables: age at study 
enrolment (continuous), smoking status at study enrolment 
(never smoker, ex- smoker, current smoker), healthcare re-
gion (North, Uppsala- Örebro, Stockholm, West, South- East, 
South), country of birth (born in Sweden with both parents 
born in Sweden, born in Sweden with one parent born in 
Sweden, born in Sweden with both parents born abroad, born 
abroad, missing) and highest education at study enrolment 
(pre- upper secondary school <9  years, pre- upper second-
ary school 9  years, max. 2  years upper secondary school, 
3 years upper secondary school, post- upper secondary school 
<3  years, post- upper secondary school ≥3  years including 
university, missing). We additionally adjusted the analysis of 
WC for height (continuous).
We tested the interaction between cohort and WC and 
ABSI, respectively, in relation to PCa risk, using the likeli-
hood ratio test. We found no interaction between cohort and 
WC (p = 0.7921) or between cohort and ABSI (p = 0.4984), 
which supported the pooling of the cohorts into one analy-
sis. The assumption of proportional hazards was examined 
for the relationship of scaled Schoenfeld residuals with time 
and appeared to be violated for both age at study enrolment 
and birth period. However, as including age as a stratum did 
not alter the estimates, we only stratified for birth period and 
cohort (to control for any differences in PCa hazards over time 
between the cohorts). The heterogeneity between the PCa 
risk categories was calculated using the duplication method 
for Cox regression as described by Lunn and McNeil.39
In the analysis of PCa cases only, Cox regression models 
with time since diagnosis as the time scale were used to cal-
culate HRs and 95% CIs for PCa- specific mortality by levels 
of WC, ABSI and BMI. Adjustments were the same as in the 
full population analysis for smoking status, healthcare region, 
country of birth and height, and additional adjustments were 
made for age at PCa diagnosis (continuous), highest educa-
tion closest to diagnosis, income closest to diagnosis (<158, 
158– 193, 193– 230, ≥230 kSEK/year, missing), source of in-
come closest to diagnosis (work, studies, care of child/fam-
ily, sick, unemployed, early retirement, social benefits, labour 
market policy activity, pensioner, no income, missing), civil 
status closest to diagnosis (unmarried, married, divorced, 
widower, missing), comorbidity according to the Charlson 
comorbidity index (none, mild, severe), primary treatment 
(conservative, curative, non- curative, missing) and PCa risk 
category (in the analysis for total PCa). We analysed WC as 
a continuous variable (per 10 cm) and in categories (<94 cm, 
94– 102 cm, >102 cm) using the World Health Organisation's 
cut- offs for WC in Caucasian men.40 ABSI was calculated 
with the formula27: 1000 × WC × weight −2/3 × height 5/6, 
and analysed per standard deviation (SD) increase. In addi-
tion, BMI per 5 kg/m2 was analysed to explore whether any 
differences in associations with BMI compared to our previ-
ous analysis could be due to a smaller study sample.
A total of 13,912 men had at least one repeated mea-
surement of WC. Therefore, we calculated the regression 
dilution ratio (RDR) of WC, ABSI and BMI, in order to 
account for the short- and long- term intra- individual vari-
ation including random measurement errors.41 The RDR 
was 0.85 for WC and 0.95 for ABSI in the full population, 
and 0.91 for WC and 0.94 for ABSI among PCa cases only. 
The RDR for BMI was 0.90 for both the full population and 
the cases. All HRs were RDR- corrected using the formula: 
HRcorrected = exp(log[HRoriginal]/RDR).
Statistical tests were two- sided and data were analysed 
with STATA release 13 (College Station, StataCorp LP).
3 |  RESULTS
Baseline characteristics of the 58,457 men according to WC 
are presented in Table 1, and according to cohort in Table S1 
in the Appendix 1. During on average 10.7 years (SD 6.3) of 
follow- up, 3290 men were diagnosed with PCa, of which 387 
died from the disease. For these 3290 men, clinical character-
istics are presented in Table 2. A total of 2470 men had suffi-
cient information in the NPCR for cancer risk categorisation 
and 2340 men also on the main reason for PCa detection. The 
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median time of follow- up among PCa cases from the date of 
study enrolment until PCa diagnosis was 8.5 years and the 
median time from PCa diagnosis to PCa- specific mortality 
was 4.1 years.
WC was negatively associated with the risk of total PCa 
(HR per 10  cm, 0.95; 95% CI 0.92– 0.99) and all localised 
PCa (HR per 10 cm, 0.93, 95% CI 0.88– 0.96), but was not 
associated with more advanced PCa (p for heterogeneity be-
tween risk groups = 0.09) (Table 3). For all localised PCa 
cases, the negative association with WC was the strongest 
for asymptomatic PCa cases (HR per 10 cm, 0.87; 95% CI 
0.81– 0.94), and there were no associations with localised 
PCa cases detected by LUTS or any other symptoms (HR 
per 10  cm, 0.95; 95% CI 0.88– 1.02); however, confidence 
T A B L E  1  Baseline characteristics of the 58,457 men in the study, in total and according to waist circumference
Baseline characteristic
Per waist circumference, cm
Total <94 94– 102 >102
(n = 58,457) (n = 24,379) (n = 17,473) (n = 16,605)
Cohort (year of baseline examination), n (%)
Västerbotten Intervention Programme (2003– 2016) 37,396 (64) 14,782 (60) 11,349 (65) 11,265 (68)
Northern Sweden Monica Study (1986– 2014) 4000 (7) 1967 (8) 1139 (6) 894 (5)
Malmö Diet and Cancer Study (1991– 1996) 11,615 (20) 6014 (25) 3235 (19) 2366 (14)
Malmö Preventive Project (2002– 2006) 5446 (9) 1616 (7) 1750 (10) 2080 (13)
Age at study enrolment, years
Mean (SD) 53.0 (10.2) 51.7 (10.5) 53.7 (9.9) 54.1 (9.9)
Height, cm
Mean (SD) 178.1 (6.8) 177.1 (6.7) 178.4 (6.7) 179.2 (6.8)
Weight, kg
Mean (SD) 85.4 (13.7) 75.2 (7.8) 85.7 (7.1) 100.0 (12.4)
Body mass index, kg/m2
Mean (SD) 26.9 (3.9) 24.0 (2.1) 26.9 (1.9) 31.1 (3.5)
Categories, n (%)
<25 19,352 (33) 16,588 (67) 2620 (15) 144 (1)
25– 30 28,510 (49) 7737 (32) 13,846 (79) 6927 (42)
>30 10,595 (18) 54 (1) 1007 (6) 9534 (57)
Smoking status, n (%)
Never smoker 32,069 (55) 14,287 (59) 9518 (54) 8264 (50)
Ex- smoker 15,854 (27) 5426 (22) 4987 (29) 5441 (33)
Current smoker 8871 (15) 4011 (16) 2472 (14) 2388 (14)
Missing 1663 (3) 655 (3) 496 (3) 512 (3)
Highest education, n (%)a 
Pre- upper secondary school <9 years 7209 (12) 2828 (12) 2214 (13) 2167 (13)
Pre- upper secondary school 9 years 4566 (8) 1573 (6) 1397 (8) 1596 (10)
Max 2 years upper secondary school 19,961 (34) 7694 (32) 6047 (35) 6220 (37)
3 years upper secondary school 9563 (16) 4102 (17) 2802 (16) 2659 (16)
Post- upper secondary school <3 years 7568 (13) 3288 (13) 2301 (13) 1979 (12)
Post- upper secondary school ≥3 years 9343 (16) 4785 (20) 2656 (15) 1902 (11)
Missing 247 (1) 109 (1) 56 (1) 82 (1)
Country of birth, n (%)
Born in Sweden and both parents born in Sweden 51,116 (87) 21,253 (87) 15,311 (88) 14,552 (88)
Other 7341 (13) 3126 (13) 2162 (12) 2053 (12)
Abbreviation: SD, standard deviation.
aDetermined by the Swedish Longitudinal integration database for health insurance and labour market studies. 
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intervals were largely overlapping between groups (Figure 1). 
WC was not associated with the risk of dying of PCa in the 
full population (HR per 10 cm, 1.07, 95% CI 0.95– 1.20) or 
among PCa cases (HR per 10 cm, 1.04, 95% CI 0.92– 1.19). 
WC was positively associated with all- cause mortality (HR 
per 10 cm, 1.08, 95% CI 1.01– 1.06) among PCa cases.
ABSI was not associated with the risk of PCa in total or 
in any cancer risk category. The HR per SD was 0.97; 95% 
CI 0.93– 1.00 for total PCa, 0.97; 95% CI 0.93– 1.02 for lo-
calised PCa, and 0.96; 95% CI 0.86– 1.06 for advanced PCa 
(Table  3). No associations were found between ABSI and 
PCa- specific mortality in the full population (HR per SD, 
0.99; 95% CI 0.90– 1.09) or among PCa cases only (HR per 
SD, 0.96; 95% CI 0.85– 1.08), nor with all- cause mortality 
(HR per SD, 1.07, 95% CI 0.99– 1.14) among PCa cases.
We found a negative association between BMI and 
the risk of localised PCa (HR per 5 kg/m2, 0.90; 95% CI 
0.85– 0.97) and no association with advanced PCa (HR 
per 5  kg/m2, 1.04; 95% CI 0.90– 1.21) (Table  3), which 
are in agreement with our previous study of BMI and PCa 
risk with a much larger study sample (HRs per 5 kg/m2, 
0.93; 95% CI 0.91– 0.96, and 1.01; 95% CI 0.97– 1.06, 
respectively). The lack of association between BMI and 
death from PCa in the full population (HR per 5 kg/m2, 
1.13; 95% CI 0.97– 1.35) and among PCa cases (HR per 
5 kg/m2, 1.17; 95% CI 0.98– 1.42) were about the same 
magnitude as of our previously found associations be-
tween BMI and PCa- specific mortality (HRs per 5 kg/m2, 
1.12; 95% CI 1.08– 1.17, and 1.13; 95% CI 1.08– 1.20, 
respectively).
F I G U R E  1  Hazard ratios (95% confidence intervals [CIs]) for incident localised prostate cancer, assigned a cancer risk category and by 
mode of detection, according to waist circumference per 10 cm. Prostate cancer risk categories were categorised into localised low- risk = T1- 2, 
Gleason score 2- 6 and PSA <10 ng/ml; localised intermediate- risk = T1- 2, Gleason score 7 and/or PSA 10 to <20 ng/ml; and localised high- risk 
= T3 and/or Gleason score 8- 10 and/or PSA 20 to <50 ng/ml. Hazard ratios (95% CI) were calculated by Cox regression with attained age as time 
scale, stratified on cohort and birth decade, and adjusted for age at study entry, height, smoking status, healthcare region, country of birth, and 
highest education. Hazard ratios of waist circumference were corrected for a regression dilution ratio (RDR) of 0.85. LUTS = lower urinary tract 
symptoms; PCa = prostate cancer
0.50 1.00 1.50
asymptomatic luts + other symptoms
Waist circumference,
per 10 cm
Hazard ratio (95% CI)
0.94 (0.83 to 1.06)
0.98 (0.87 to 1.12)
0.81 (0.72 to 0.91)
0.82 (0.72 to 0.93)
0.90 (0.77 to 1.05)
1.06 (0.93 to 1.22)
0.87 (0.81 to 0.94)
0.95 (0.88 to 1.02)
Hazard ratio
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4 |  DISCUSSION
In this prospective pooled cohort study, we found a negative 
association for WC with the risk of localised PCa, partially 
driven by PCa cases detected by asymptomatic PSA- testing, 
but no associations with the risk of advanced PCa or PCa- 
specific mortality.
Our results for localised PCa are in line with previous 
studies on WC and PCa risk, which indicated a negative or 
null association with localised PCa.3,4,7,9,10 Several factors 
have been hypothesised to influence the negative association 
between WC and localised PCa risk, including an enlarged 
prostate gland, hemodiluted PSA levels and less active PCa 
screening among men with obesity.14- 16 Results from our pre-
vious study of BMI and PCa risk showed that the negative 
association with localised PCa was partially driven by the 
results for asymptomatic PSA- testing,5 as with our negative 
association between WC and localised PCa that was most ev-
ident for asymptomatic PCa cases detected through a PSA- 
test. This could indicate that more active health- seeking and 
screening behaviour among men with normal weight contrib-
utes to their higher risk of localised PCa.
In this study on waist measures, like in our prior study 
on BMI,5 we found no association with the risk of more 
advanced PCa. Our findings are in agreement with the 
lacking association between WC, waist– hip ratio and risk 
of advanced PCa found in the large study by Genkinger 
et al,6 and of a Mendelian randomisation study.42 Both 
were published after the World Cancer Research Fund 
International's Continuous Update Project report on PCa43 
and the Umbrella review of the literature on adiposity and 
cancer at major anatomical sites,44 which suggested some 
evidence of an increased risk of advanced PCa with higher 
body fatness. These later studies carry large weight in the 
field, and point at a limited role for waist measures in ad-
vanced PCa risk.
Although the association between BMI and PCa- 
specific mortality in our and other studies has been con-
sistently positive,18- 22 results from studies investigating 
WC and death from PCa have been inconsistent.3,6,23,24 
Some of the inconsistency could relate to smaller sam-
ple sizes in these studies as compared to studies of BMI. 
For example, a weak positive association between WC and 
PCa- specific mortality in the study by Genkinger et al6 is 
of the same magnitude as our non- significant finding, in-
cluding in our case- only analysis, which controls for stage 
at diagnosis and any potential detection bias that may be 
at play in a full- population analysis. The emerging picture 
of an increased risk of PCa- specific mortality, but not ad-
vanced disease, for obesity assessed by BMI and to lesser 
extent by WC, appears contradictory. Markers of abdomi-
nal obesity such as WC reflect metabolic aberrations more 
strongly than does BMI and could potentially clarify the 
relationship between obesity and PCa. However, the find-
ings of our and other studies have not shown clearer or 
different associations for adiposity markers than for BMI 
in relation to PCa incidence and mortality.
Strengths of this study include the prospective study de-
sign, the population- based data, the large sample size pro-
viding enough statistical power to investigate abdominal 
adiposity in relation to localised and advanced PCa risk sepa-
rately, detailed and highly valid PCa data from the NPCR37,38 
and on confounders, and the availability of repeated measures 
to correct for short- and long- term intra- individual variation 
of WC, which, uncorrected, would result in underestimated 
hazard ratios.41 Limitations of this study concern the smaller 
sample size and therefore less robust results in the individual 
cancer risk categories and by mode of PCa detection com-
pared to our larger source population.
In conclusion, the findings of WC in this study support 
the results from our previous study of BMI in a larger source 
population of negative associations with the risk of total PCa 
and localised PCa, partially driven by PSA- detected PCa 
cases, and no association with clinically manifest PCa. The 
emerging picture of an increased risk of PCa- specific mor-
tality, but not advanced disease, for obesity assessed by BMI 
and to lesser extent by WC, appears contradictory and re-
quires further examination.
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